Mauna Kea Technologies SA announced that it has received 2.3 million in a round of funding on May 31, 2023. The transaction included participation from new investor Tasly Pharmaceutical Group Co., Ltd.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.39 EUR | +2.77% | 0.00% | -17.20% |
Apr. 25 | Mauna Kea Technologies SA Provides Sales Guidance for the Year 2024 | CI |
Apr. 03 | Mauna Kea: first Italian center for Cellvizio | CF |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
15.36 CNY | +3.09% | +0.20% | 3.15B | ||
0.39 EUR | +2.77% | 0.00% | 25.62M | ||
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-17.20% | 25.62M | |
-12.91% | 19.08B | |
-46.21% | 2.65B | |
+18.15% | 1.87B | |
-3.12% | 1.61B | |
+23.78% | 1.21B | |
-10.69% | 1.02B | |
-20.89% | 905M | |
-7.14% | 716M | |
-18.10% | 682M |
- Stock Market
- Equities
- ALMKT Stock
- News Mauna Kea Technologies
- Mauna Kea Technologies SA announced that it has received €2.3 million in funding from Tasly Pharmaceutical Group Co., Ltd